Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by Mission Wealth Management LP

Mission Wealth Management LP raised its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 12.8% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 12,086 shares of the biopharmaceutical company’s stock after acquiring an additional 1,367 shares during the period. Mission Wealth Management LP’s holdings in Gilead Sciences were worth $979,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in GILD. Brookstone Capital Management increased its position in Gilead Sciences by 10.6% during the 3rd quarter. Brookstone Capital Management now owns 14,547 shares of the biopharmaceutical company’s stock worth $1,141,000 after purchasing an additional 1,390 shares during the period. Cambridge Investment Research Advisors Inc. boosted its stake in shares of Gilead Sciences by 46.9% in the third quarter. Cambridge Investment Research Advisors Inc. now owns 202,220 shares of the biopharmaceutical company’s stock valued at $15,154,000 after buying an additional 64,569 shares in the last quarter. Raymond James & Associates raised its position in Gilead Sciences by 13.5% in the third quarter. Raymond James & Associates now owns 2,325,094 shares of the biopharmaceutical company’s stock worth $174,242,000 after acquiring an additional 276,676 shares in the last quarter. Stratos Wealth Partners LTD. lifted its holdings in Gilead Sciences by 7.9% in the third quarter. Stratos Wealth Partners LTD. now owns 107,544 shares of the biopharmaceutical company’s stock valued at $8,059,000 after acquiring an additional 7,920 shares during the period. Finally, Moody Lynn & Lieberson LLC grew its stake in shares of Gilead Sciences by 3.4% during the 3rd quarter. Moody Lynn & Lieberson LLC now owns 5,056 shares of the biopharmaceutical company’s stock worth $379,000 after purchasing an additional 165 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling

In related news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $72.96, for a total value of $145,920.00. Following the transaction, the insider now owns 96,304 shares in the company, valued at $7,026,339.84. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.16% of the stock is currently owned by insiders.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $65.51 on Thursday. The company has a current ratio of 0.98, a quick ratio of 0.72 and a debt-to-equity ratio of 1.08. The company has a market cap of $81.57 billion, a PE ratio of 181.97, a P/E/G ratio of 1.31 and a beta of 0.22. The company’s fifty day simple moving average is $70.87 and its 200-day simple moving average is $76.01. Gilead Sciences, Inc. has a 52 week low of $64.63 and a 52 week high of $87.86.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) EPS for the quarter, topping analysts’ consensus estimates of ($1.49) by $0.17. The company had revenue of $6.69 billion for the quarter, compared to analysts’ expectations of $6.36 billion. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. The firm’s quarterly revenue was up 5.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.37 earnings per share. As a group, equities research analysts anticipate that Gilead Sciences, Inc. will post 3.74 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, June 27th. Investors of record on Friday, June 14th will be issued a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a yield of 4.70%. The ex-dividend date is Friday, June 14th. Gilead Sciences’s payout ratio is 855.56%.

Analyst Upgrades and Downgrades

GILD has been the subject of a number of research analyst reports. HSBC upgraded Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price target for the company in a research report on Wednesday, April 24th. Truist Financial lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating and cut their price objective for the company from $91.00 to $82.00 in a research report on Thursday, February 22nd. Cantor Fitzgerald decreased their target price on shares of Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 7th. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a report on Friday, April 26th. Finally, Royal Bank of Canada decreased their price objective on Gilead Sciences from $76.00 to $74.00 and set a “sector perform” rating on the stock in a report on Friday, April 26th. Eleven research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Gilead Sciences presently has an average rating of “Hold” and a consensus target price of $83.69.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.